Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × Lymphoma, Follicular × tazemetostat × Clear all

Phase

Status

Completed 5 Recruiting 4 Withdrawn 3 Active not recruiting 3 Terminated 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1 Lymphoma, Follicular 1 Lymphoma 1 Immunoblastic Lymphadenopathy 1 Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Specimen Handling 2 Magnetic Resonance Spectroscopy 2 Biopsy 2 tazemetostat 1 Lenalidomide 1 Exercise 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06575686 2026-01-21

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

City of Hope Medical Center

Phase 2 Suspended

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡